Literature DB >> 15373830

The tumor suppressor HIC1 (hypermethylated in cancer 1) is O-GlcNAc glycosylated.

Tony Lefebvre1, Sébastien Pinte, Cateline Guérardel, Sophie Deltour, Nathalie Martin-Soudant, Marie-Christine Slomianny, Jean-Claude Michalski, Dominique Leprince.   

Abstract

HIC1 (hypermethylated in cancer 1) is a transcriptional repressor containing five Krüppel-like C(2)H(2) zinc fingers and an N-terminal dimerization and autonomous repression domain called BTB/POZ. Here, we demonstrate that full-length HIC1 proteins are modified both in vivo and in vitro with O-linked N-acetylglucosamine (O-GlcNAc). This is a highly dynamic glycosylation found within the cytosolic and the nuclear compartments of eukaryotes. Analysis of [(3)H]Gal-labeled tryptic peptides indicates that HIC1 has three major sites for O-GlcNAc glycosylation. Using C-terminal deletion mutants, we have shown that O-GlcNAc modification of HIC1 proteins occurred preferentially in the DNA-binding domain. Nonglycosylated and glycosylated forms of full-length HIC1 proteins separated by wheat germ agglutinin affinity purification, displayed the same specific DNA-binding activity in electrophoretic mobility shift assays proving that the O-GlcNAc modification is not directly implicated in the specific DNA recognition of HIC1. Intriguingly, N-terminal truncated forms corresponding to BTB-POZ-deleted proteins exhibited a strikingly differential activity, as the glycosylated truncated forms are unable to bind DNA whereas the unglycosylated ones do. Electrophoretic mobility shift assays performed with separated pools of glycosylated and unglycosylated forms of a construct exhibiting only the DNA-binding domain and the C-terminal tail of HIC1 (residues 399-714) and supershift experiments with wheat germ agglutinin or RL-2, an antibody raised against O-GlcNAc residues, fully corroborated these results. Interestingly, these truncated proteins are O-GlcNAc modified in their C-terminal tail (residues 670-711) and not in the DNA-binding domain, as for the full-length proteins. Thus, the O-GlcNAc modification of HIC1 does not affect its specific DNA-binding activity and is highly sensitive to conformational effects, notably its dimerization through the BTB/POZ domain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373830     DOI: 10.1111/j.1432-1033.2004.04316.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  15 in total

Review 1.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

Review 2.  Nutrient regulation of signaling and transcription.

Authors:  Gerald W Hart
Journal:  J Biol Chem       Date:  2019-01-09       Impact factor: 5.157

Review 3.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

Review 4.  Regulation of protein degradation by O-GlcNAcylation: crosstalk with ubiquitination.

Authors:  Hai-Bin Ruan; Yongzhan Nie; Xiaoyong Yang
Journal:  Mol Cell Proteomics       Date:  2013-07-03       Impact factor: 5.911

5.  O-GlcNAcylation/phosphorylation cycling at Ser10 controls both transcriptional activity and stability of delta-lactoferrin.

Authors:  Stéphan Hardivillé; Esthelle Hoedt; Christophe Mariller; Monique Benaïssa; Annick Pierce
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

Review 6.  Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease.

Authors:  Gerald W Hart; Chad Slawson; Genaro Ramirez-Correa; Olof Lagerlof
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

7.  Combined Antibody/Lectin Enrichment Identifies Extensive Changes in the O-GlcNAc Sub-proteome upon Oxidative Stress.

Authors:  Albert Lee; Devin Miller; Roger Henry; Venkata D P Paruchuri; Robert N O'Meally; Tatiana Boronina; Robert N Cole; Natasha E Zachara
Journal:  J Proteome Res       Date:  2016-10-14       Impact factor: 4.466

8.  An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.

Authors:  Nicolas Stankovic-Valentin; Sophie Deltour; Jacob Seeler; Sébastien Pinte; Gérard Vergoten; Cateline Guérardel; Anne Dejean; Dominique Leprince
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

Review 9.  O-GlcNAc cycling: implications for neurodegenerative disorders.

Authors:  Brooke D Lazarus; Dona C Love; John A Hanover
Journal:  Int J Biochem Cell Biol       Date:  2009-03-27       Impact factor: 5.085

10.  Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control.

Authors:  B Zhang; K J Chambers; D Leprince; D V Faller; S Wang
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.